ASCO Genitourinary Cancers Symposium 2026: key results and trends

Among pts evaluated for DFS (n = 135 in EV + pembro arm; n = 129 in control arm), median DFS was not reached vs 23.6 mo (HR 0.37; 95% CI 0.23–0.59).

Median (range) DOR was 23.0 mo (2.0–44.3+) with bel + lenva vs 12.3 mo (1.8+–35.9+) with cabo at IA2.

Gem-iDRS + CET did not show superior BI-EFS over CRT (HR, 1.71 [95% CI, 1.16-2.53]); 24-mo rates were 58.5% vs 66.5%, respectively.

There was no improvement of cPFS with cabazitaxel (HR: 1.11 [0.87-1.41]; 6-year cPFS rates: 67.2% vs 71.4%).

An rPFS benefit for DARO vs PBO was seen across all comorbid (≤4, HR 0.46, 95% CI 0.32–0.65; >4, HR 0.58, 95% CI 0.36–0.93) and conmed (≤4, HR 0.48, 95% CI 0.32–0.72; >4, HR 0.61, 95% CI 0.38–0.97) subgroups.

Overall incidences of grade ≥3 AEs and serious AEs were 50.7% and 26.6%, respectively, in the 177 Lu-PSMA-617 arm and 43.0% and 22.8% in the control arm.

In the avelumab + axitinib vs sunitinib arms, respectively, treatment-related adverse events of any grade occurred in 100% vs 97.2% pts, including grade ≥3 events in 73.3% vs 61.1%, and led to permanent discontinuation of all study drugs in 0% vs 16.7%.

Two doses of INAIC with MMC significantly improved 3- and 5-year PFS rates compared to controls (100% vs. 92.1% and 85.8%; HR 0.078, P = 0.014) and 3- and 5-year CFS rates (100% vs. 97.4% and 91.1%; HR 0.078, P = 0.014) using Firth’s penalized likelihood method.

The SRT+eARB arm had better PFS when compared to the SRT+sADT arm (HR=0.62, 80% CI: 0.42-0.91, one-sided p=0.052).

In per protocol analysis of pts who received 4 cycles of I/N +/- SBRT, 12-month PFS was 46% vs 56%, ORR was 50% vs 44%, and 18-month OS was 74% vs 79%, for I/N+SBRT (n = 24) vs I/N alone (n = 16).

PSA response rates were similar at 3 (82% with Apa vs 75% with ADT, p = 0.3), 6 (84% vs 73%, p = 0.12) and 9 (76% vs 74%, p = 0.9) months.

Adjusted for prognostic factors, median PFS was 28 months after MDT+ICI and 17 months after MDT (HR, 0.57; 95% CI: 0.31 to 0.998; P = 0.049).